133 related articles for article (PubMed ID: 29101824)
1. Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab.
Gujral DM; Lloyd G; Bhattacharyya S
Breast; 2018 Feb; 37():64-71. PubMed ID: 29101824
[TBL] [Abstract][Full Text] [Related]
2. Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Henriksen PA; Hall P; Oikonomidou O; MacPherson IR; Maclean M; Lewis S; McVicars H; Broom A; Scott F; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Payne JR; Newby DE; Mills NL; Lang NN
Circ Heart Fail; 2022 Jul; 15(7):e009445. PubMed ID: 35766037
[TBL] [Abstract][Full Text] [Related]
3. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
Henriksen PA; Hall P; MacPherson IR; Joshi SS; Singh T; Maclean M; Lewis S; Rodriguez A; Fletcher A; Everett RJ; Stavert H; Broom A; Eddie L; Primrose L; McVicars H; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Williams MC; Japp A; Payne JR; Newby DE; Mills NL; Oikonomidou O; Lang NN
Circulation; 2023 Nov; 148(21):1680-1690. PubMed ID: 37746692
[TBL] [Abstract][Full Text] [Related]
4. Effect of increase in heart rate after anthracycline chemotherapy on subsequent left ventricular dysfunction.
Kintsu M; Odajima S; Takeuchi K; Ichikawa Y; Todo S; Ota E; Yamauchi Y; Shiraki H; Yamashita K; Fukuda T; Hisamatsu E; Minami H; Hirata KI; Tanaka H
J Cardiol; 2024 Aug; 84(2):119-125. PubMed ID: 37949314
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular sequelae of trastuzumab and anthracycline in long-term survivors of breast cancer.
Glen C; Morrow A; Roditi G; Hopkins T; Macpherson I; Stewart P; Petrie MC; Berry C; Epstein F; Lang NN; Mangion K
Heart; 2024 Apr; 110(9):650-656. PubMed ID: 38103912
[TBL] [Abstract][Full Text] [Related]
6. Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function.
Chotenimitkhun R; D'Agostino R; Lawrence JA; Hamilton CA; Jordan JH; Vasu S; Lash TL; Yeboah J; Herrington DM; Hundley WG
Can J Cardiol; 2015 Mar; 31(3):302-7. PubMed ID: 25662284
[TBL] [Abstract][Full Text] [Related]
7. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
Neilan TG; Quinaglia T; Onoue T; Mahmood SS; Drobni ZD; Gilman HK; Smith A; Heemelaar JC; Brahmbhatt P; Ho JS; Sama S; Svoboda J; Neuberg DS; Abramson JS; Hochberg EP; Barnes JA; Armand P; Jacobsen ED; Jacobson CA; Kim AI; Soumerai JD; Han Y; Friedman RS; Lacasce AS; Ky B; Landsburg D; Nasta S; Kwong RY; Jerosch-Herold M; Redd RA; Hua L; Januzzi JL; Asnani A; Mousavi N; Scherrer-Crosbie M
JAMA; 2023 Aug; 330(6):528-536. PubMed ID: 37552303
[TBL] [Abstract][Full Text] [Related]
8. Left Ventricular Mass Change After Anthracycline Chemotherapy.
Jordan JH; Castellino SM; Meléndez GC; Klepin HD; Ellis LR; Lamar Z; Vasu S; Kitzman DW; Ntim WO; Brubaker PH; Reichek N; D'Agostino RB; Hundley WG
Circ Heart Fail; 2018 Jul; 11(7):e004560. PubMed ID: 29991488
[TBL] [Abstract][Full Text] [Related]
9. Prevention of anthracycline-t and trastuzumabinduced decline in left ventricular ejection fraction with angiotensin-converting enzyme inhibitors or angiotensin receptor blocker: a narrative systematic review of randomised controlled trials.
Lee S; Alsamarrai A; Xiao A; Wang TKM
Intern Med J; 2024 Jun; ():. PubMed ID: 38874281
[TBL] [Abstract][Full Text] [Related]
10. Hypertension Severity and Declines in Left Ventricular Ejection Fraction Among Women Receiving Adjuvant Chemotherapy for Breast Cancer (WF-97415 UPBEAT).
Garg R; D'Agostino RB; O'Connell N; Lesser GJ; Salloum FN; Hines AL; Meléndez GC; Jordan JH; Ky B; Wagner LI; Sutton AL; Bottinor W; Olson KC; Ladd AC; Hundley WG;
Hypertension; 2024 Jun; 81(6):1365-1373. PubMed ID: 38634292
[TBL] [Abstract][Full Text] [Related]
11. From 60% to 5% in 12 Weeks: A Trastuzumab-Induced Left Ventricular Ejection Fraction Drop.
Pan Q; Zhao R; Graham-Hill S
Cureus; 2024 Apr; 16(4):e59172. PubMed ID: 38707046
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis to Prevent Cardiotoxicity in Patients Receiving Anthracycline for Breast Cancer: A Combined Bayesian and Frequentist Network Meta-Analysis of Randomised Controlled Trials.
Jeyaprakash P; Sangha S; Low G; Yu C; Pathan F; Negishi K
Heart Lung Circ; 2024 May; 33(5):710-720. PubMed ID: 38184425
[TBL] [Abstract][Full Text] [Related]
13. Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter.
Dang CT; Yu AF; Jones LW; Liu J; Steingart RM; Argolo DF; Norton L; Hudis CA
J Clin Oncol; 2016 Apr; 34(10):1030-3. PubMed ID: 26834055
[No Abstract] [Full Text] [Related]
14. Heart failure related to contemporary breast cancer treatment.
Durkin M; DeJesus N
JAAPA; 2024 Apr; 37(4):29-33. PubMed ID: 38531031
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity of Anthracyclines.
Cardinale D; Iacopo F; Cipolla CM
Front Cardiovasc Med; 2020; 7():26. PubMed ID: 32258060
[TBL] [Abstract][Full Text] [Related]
16. The Role of Angiotensin-Converting Enzyme Inhibitors and β-Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Patients.
Brown SA; Okwuosa TM; Barac A; Volgman AS
J Am Heart Assoc; 2020 Jan; 9(2):e015327. PubMed ID: 31960742
[No Abstract] [Full Text] [Related]
17. Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies.
Agunbiade TA; Zaghlol RY; Barac A
Methodist Debakey Cardiovasc J; 2019; 15(4):250-257. PubMed ID: 31988685
[TBL] [Abstract][Full Text] [Related]
18. [Anthracycline-induced Heart Failure: Treatment and Recovery Prospects].
Vitsenya MV; Potekhina AV; Filatova AY; Stukalova OV; Ageev FT
Kardiologiia; 2024 Apr; 64(4):79-84. PubMed ID: 38742519
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report.
Minichillo S; Gallelli I; Barbieri E; Cubelli M; Rubino D; Quercia S; Dall'Olio M; Rapezzi C; Zamagni C
BMC Cancer; 2017 Nov; 17(1):722. PubMed ID: 29115937
[TBL] [Abstract][Full Text] [Related]
20. The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity.
Blanter JB; Frishman WH
Cardiol Rev; 2019; 27(5):256-259. PubMed ID: 31008768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
